Enveda raises $311M Series E at $2B valuation to advance nature-derived AI drug discovery.
The AMW Read
Incremental funding update for an already-known AI-bio player advancing candidates into clinical trials, with sub-segment relevance to the bio-platform vs. clinical-evidence debate but no resolution of it.
Enveda raises $311M Series E at $2B valuation to advance nature-derived AI drug discovery.
Enveda, a biotech startup that mines plants and microbes for drug candidates using AI, closed a $311 million Series E led by Catalio Capital Management, with participation from Iconiq and others. The round values the company at $2 billion, double its valuation from a year earlier. Founded in 2019 by Viswa Colluru, an early employee at Recursion Pharmaceuticals, Enveda is currently testing several AI-discovered candidates in human trials, including one for severe skin conditions and another designed to help patients maintain weight loss after stopping GLP-1 drugs.
No AI-discovered drug has reached FDA approval yet, and that gap is the central tension in vertical healthcare AI: capital keeps flowing toward companies with candidates in the clinic, well ahead of any regulatory proof that the approach works. Enveda's bet is structurally different from pure computational drug design — it treats natural chemical diversity in plants and microbes as a data source that generative chemistry alone struggles to replicate, which is part of why investors are pricing it well above typical clinical-stage biotech multiples.
For investors, a doubled valuation with zero approved drugs signals that capital is being underwritten on trial-stage momentum rather than outcomes, raising the stakes on Enveda's ongoing readouts. For builders in the space, the natural-product sourcing pipeline is a reminder that differentiated data acquisition, not just model architecture, is becoming the harder moat to replicate in AI-driven drug discovery.